MEDICLINIC INTERNATIONAL PLC - 2018 Capital Markets Day

Release Date: 28/06/2018 08:00
Code(s): MEI
 
Wrap Text
2018 Capital Markets Day

Mediclinic International plc
(Incorporated in England and Wales)
Company Number: 08338604
LSE Share Code: MDC
JSE Share Code: MEI
NSX Share Code: MEP
ISIN: GB00B8HX8Z88
LEI: 2138002S5BSBIZTD5I60
(“Mediclinic”, the “Company” or the “Group”)

28 June 2018

2018 Capital Markets Day

Mediclinic International plc, the international private healthcare services group, will today
host a Capital Markets Day event and site visit for analysts and investors in Zurich, Switzerland.
No new material information will be provided during the event and guidance remains
unchanged with trading in line with expectations.

The event will be available via a live webcast at 08:00BST/09:00CEST, details of which can be
found below.

The event will include presentations from the Group’s CEO and CFO in addition to operational
reviews from the divisional CEO’s of Hirslanden, Mediclinic Southern Africa and Mediclinic
Middle East.

The key theme for the day is Mediclinic’s tailored approach to value creation focusing on:
     • Our diversified international presence and unified focus
     • Strong healthcare market potential
     • Our unique approach to creating value putting patients at the core of our business
     • Our focus on international growth opportunities
     • Our management skills and expertise
     • Financial discipline across the Group

Webcast details
A live webcast of today’s presentations along with the agenda and supporting material can be
accessed via the Group’s Investor Relations website. Please register for the event, which starts
at 08:00 BST/09:00 CEST, via the following link:

https://edge.media-server.com/m6/p/q3ui9j2u

A replay facility will be available on the website from Friday 29 June 2018.

About Mediclinic International plc
Mediclinic is an international private healthcare services group, established in South Africa in
1983, with current operating divisions in Southern Africa (South Africa and Namibia),
Switzerland and the United Arab Emirates. Its core purpose is to enhance the quality of life of
patients by providing acute care, specialist-orientated, multi-disciplinary healthcare services.
Mediclinic also holds a 29.9% interest in Spire Healthcare Group plc, an LSE-listed and UK-
based private healthcare group.

As at the date of this announcement, Mediclinic comprises 75 hospitals and 28 outpatient
clinics. Hirslanden operates 17 private hospitals and 4 clinics in Switzerland with more than 1
800 inpatient beds; Mediclinic Southern Africa operates 49 hospitals and 2 day clinics
throughout South Africa and 3 hospitals in Namibia with more than 8 100 inpatient beds in
total; and Mediclinic Middle East operates 6 hospitals and 22 clinics with more than 700
inpatient beds in the United Arab Emirates.

Mediclinic has a primary listing on the Main Market of the LSE in the United Kingdom, with
secondary listings on the JSE in South Africa and the NSX in Namibia.
For further information, please contact:

Investor Relations, Mediclinic International plc
James Arnold, Head of Investor Relations
ir@mediclinic.com
+44 (0)20 3786 8181

Media queries
FTI Consulting
Brett Pollard/Debbie Scott – UK
+44 (0)20 3727 1000
Sherryn Schooling – South Africa
+27 (0)21 487 9000

Registered address: 6th Floor, 65 Gresham Street, London, EC2V 7NQ, United Kingdom
Website: www.mediclinic.com
Corporate brokers: Morgan Stanley & Co International plc and UBS Investment Bank
JSE sponsor: Rand Merchant Bank (A division of FirstRand Bank Limited)
NSX sponsor: Simonis Storm Securities (Pty) Ltd

Date: 28/06/2018 08:00:00 Produced by the JSE SENS Department. The SENS service is an information dissemination service administered by the JSE Limited ('JSE'). 
The JSE does not, whether expressly, tacitly or implicitly, represent, warrant or in any way guarantee the truth, accuracy or completeness of
 the information published on SENS. The JSE, their officers, employees and agents accept no liability for (or in respect of) any direct, 
indirect, incidental or consequential loss or damage of any kind or nature, howsoever arising, from the use of SENS or the use of, or reliance on,
 information disseminated through SENS.

Email this JSE Sens Item to a Friend.

Share This Story